# Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

> **NCT07349758** · PHASE1 · RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 24 (estimated)

## Conditions studied

- Healthy Volunteer
- HIV Prevention

## Interventions

- **DRUG:** tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg

## Key facts

- **NCT ID:** NCT07349758
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-06
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07349758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07349758, "Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07349758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*